Eisai/Biogen Maintain Lead Over Lilly In New Race To Alzheimer’s Approval

Full Approval Filing May Quickly Follow Accelerated US FDA Decision

The US FDA accepted an application for accelerated approval and set a 6 January action date, giving lecanemab ample time to reach the market ahead of Lilly’s competing anti-amyloid antibody donanemab.

Up arrows on blue background illustration
Eisai/Biogen have a nearly two-month lead over Lilly • Source: Shutterstock

Eisai Co., Ltd. and Biogen, Inc. remain at least a few months ahead of Eli Lilly and Company in the race to win accelerated approval and rapidly bring a second amyloid-targeting antibody to market in the US. Eisai and Biogen announced on 5 July that the Food and Drug Administration accepted their biologics license application (BLA) for lecanemab and granted priority review, setting a 6 January action date for the early Alzheimer’s disease therapy.

If approved, lecanemab (BAN2401) would not be the first anti-amyloid antibody that the partners have brought to market with an...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip